Fig. 3
From: YTHDF2 alleviates cardiac hypertrophy via regulating Myh7 mRNA decoy
YTHDF2 plays a protective role on cardiac hypertrophy in vivo. A HE staining for the assessment of gross cardiac enlargement of mice injected with AAV-YTHDF2 or control AAV through tail vein for 3 weeks, then subjected to TAC for 4 weeks. B Statistical analysis of the heart weight (HW)/body weight (BW) ratios of mice subjected to TAC surgery for 4 weeks (n = 6 mice per group; *p < 0.05 versus sham group). C WGA staining (Green) was used to measure cardiomyocyte size in the heart tissues of TAC mice. D Statistical analysis of the cross section areas of the indicated group. E Representative results of the Masson staining to assess fibrosis of the mouse heart tissues. F Detection of left ventricular end-diastolic diameter (LVEDd) in mice, n = 6. G HE staining for the assessment of gross cardiac enlargement of mice injected with AAV-si-YTHDF2 or control AAV through tail vein for 3 weeks, then subjected to TAC for 4 weeks. H Statistical analysis of the heart weight (HW)/body weight (BW) ratios of mice subjected to TAC surgery for 4 weeks (n = 6 mice per group; *p < 0.05 versus sham group). I WGA staining (Green) was used to measure cardiomyocyte size in the heart tissues of TAC mice. J Statistical analysis of the cross section areas of the insdicated group. K Representative results of the Masson staining to assess fibrosis of the mouse heart tissues. L Detection of left ventricular end-diastolic diameter (LVEDd) in mice, n = 6. *P < 0.05